Valiant Organics Ltd Q1 FY2023 Concall Summary

Key Takeaways

• A blast, not a bust: Q1 was “the worst so far” for margins after a June 3 chlorination plant blast at Sarigam halted high-margin production for nearly two months; the plant restarted July 21 and insurance covers the ~₹5 Cr damage plus loss of profit.
• PAP ramp-up on track, margin reset underway: PAP volumes held ~350 MT/month and are guided to 500–550 MT/month by H2 FY23, but management reset EBITDA margin expectations to a normalised 17–18%, down from pandemic-era highs.
• Demand weakness is compounding the supply shock: Hydrogenation products (dyes/pigments) faced a second straight quarter of subdued demand linked to textiles, leaving Unit 1 at Jhagadia underutilised.
• Promoter selling is the unquantified overhang: The former MD and other promoter-group members have sold steadily since listing; management says it is “working on a solution” but offered no timeline, and no insider has bought stock despite a 61% price correction.
• What to watch next quarter: Whether chlorination utilisation reaches the promised 75–80% within weeks, whether Q2 contract renewals actually lift margins as raw-material costs stabilise, and any concrete step on the promoter-selling problem.

The Sarigam Blast: Damage, Restart & Margin Hole

• Isolated incident, contained damage: The June 3 blast in one chlorination reactor caused minor physical damage (~₹5 Cr), no loss of life, and one minor injury that has since recovered. The plant was shut completely from June 3 until receiving restart permission on July 21.
• High-margin product lost: Chlorination is one of the highest-margin products at the gross profit level, so the shutdown eroded overall EBITDA because fixed non-variable costs continued while high-margin revenue stopped.
• Restart underway, not yet normal: Operations resumed at ~60% capacity utilisation and were expected to reach 75–80% within 8–10 days of the call; full normalisation is guided for Q3.
• HCL disposal resolved: A separate volume headwind from tightened Rule 9 hazardous-waste guidelines on HCL disposal is “almost over now,” removing one drag on throughput.
• Insurance covers the hole: The ~₹5 Cr physical damage and the loss-of-profit claim are both covered; the quantification process with the insurer was still underway at the time of the call.
• Q2 still carries blast scars: Management disclosed a ~₹20 Cr revenue impact spilling into Q2, though the full margin quantification was not yet available because the insurance working was ongoing.

Mihir Shah: “Yes, it has been the worst so far.”

PAP: Volume Ramp, Margin Reset & Continuous Process

• Volume run-rate steady: PAP maintained an average run rate of ~350 MT/month in Q1 FY23, consistent with the prior quarter.
• Ramp-up timeline intact: Management guided to ~450 MT/month in August 2022 and 500–550 MT/month by H2 FY23 (Q3/Q4), pushing back on an analyst’s suggestion that 500 MT/month had been promised for Q1. Management said they are hoping to be at around 500 by Q3.
• Margin expectations reset sharply: PAP is not a 60% gross margin product at current prices (~₹550/kg); management called it a normal 17–18% EBITDA product once things stabilise, with margins improving as scale absorbs fixed costs in the ramp-up phase. Management said they are hoping to reach that margin level by Q3/Q4.
• Continuous process is a FY24 story: Test runs are ongoing, but management’s conservative view is that benefits will accrue only from Q1 FY24 onwards; the hopeful timeline is end-of-year, but no commitment was made.
• Competitive threat played down: On Starline’s lower-cost PAP technology, management said it is “too early to comment” and noted that Valiant’s PAP process produces only common salt as a co-product, while Starline’s process produces aniline as a co-product that must be marketed or disposed of.

Mihir Shah: “it was high when the pandemic was on and the prices were high, but once things are stabilizing it is not going to continue to remain a high margin product, it will be a normal 17% to 18% EBITDA kind of a product.”

Demand & Utilisation: Hydrogenation Weakness

• Dyes and pigments drag: Hydrogenation products (OA/PA from Unit 1 at Jhagadia) faced subdued demand for a second consecutive quarter, linked to weakness in the textile industry.
• Unit 1 underutilised: The Jhagadia hydrogenation Unit 1 is running at under-optimised utilisation; margin improvement is contingent on a demand recovery in dyes and pigments.
• No China dumping observed: Management noted the demand weakness is textile-cycle-driven, not a China dumping issue.
• Ammonolysis maintenance shutdown: One ammonolysis plant underwent a mandatory maintenance shutdown during the quarter, adding a small operational drag.

Raw Materials & Margin Recovery Path

• Price volatility stabilised: Key raw-material price volatility moderated to a certain extent in Q1 FY23.
• Pass-through lag is the mechanism: Cost pass-through happens on a contractual, quarterly or six-monthly basis, so the benefit of stabilised raw-material prices will only flow through when contracts renew, starting in Q2.
• Working capital relief expected: Falling raw-material prices should release working capital during the quarter, though the benefit is partially offset by the Sarigam revenue impact.
• Margins bottomed, recovery gradual: Management stated Q1 was the trough and expects gradual improvement barring unforeseen events or renewed market volatility.

Promoter Selling: The Unresolved Overhang

• Former MD selling in personal capacity: Mr. Hemchand Gala, the former Managing Director still classified as a promoter, sold shares post-blast; management stated he is no longer with the company and they have no control over or knowledge of his personal reasons.
• Timing concern deflected: When asked directly whether the blast and the heavy post-blast selling were connected, management did not address the timing, repeating only that the seller acted independently.
• Long-term trend acknowledged: An analyst noted that promoter-group selling has been continuous since listing, involving multiple management-related individuals, and called it a “real problem” eroding investor conviction. Management said they are “taking that into consideration” and “looking for a solution,” but gave no concrete steps or timeline.
• No insider buying despite 61% correction: Asked why no promoter is buying stock to show confidence amid a steep price fall and peer promoters doing so, management said they are “working on a solution” but had “nothing further to really share on this matter.”
• No company-level problem claimed: Management denied that the selling signals any fundamental business problem, attributing it to different promoters of different ages selling for their own needs at different times.

Arvind Chheda: “Mr. Hemchand Gala was Managing Director earlier he is no more with the company and if he is selling in his personal capacity we have no control on it, it may be his personal reason we are not aware we are not in that business actually.”

New Projects: Pharma Intermediates & OAP

• Pharma intermediates awaiting CTO: The small pharma intermediates plant (20 MT capacity) has completed water runs; trial runs and phased production will begin immediately once the consent-to-operate approval arrives, expected in a couple of weeks to about a month.
• High margin, small needle: The plant is high-margin but will not “move the needle too much” at current scale unless further expanded.
• OAP margin profile: OAP is described as a “little high margin” product, contributing to the FY24–25 margin uplift story.

Guidance & Commitments

Key Metrics